Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Lawitz E;Gane E;Pearlman B;Tam E;Ghesquiere W;Guyader D;Alric L;Bronowicki JP;Lester L;Sievert W;Ghalib R;Balart L;Sund F;Lagging M;Dutko F;Shaughnessy M;Hwang P;Howe AY;Wahl J;Robertson M;Barr E;Haber B;;
Lancet (London, England) 2015 Vol. 385 pp. -
228
e2015lancetefficacy

Abstract

Merck & Co, Inc.

Keywords

hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE RNA humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male adolescent aged middle aged young adult Drug Administration Schedule Comparative Study 80 and over Clinical Trial Randomized Controlled Trial Multicenter Study drug therapy combination viral load ribavirin / administration & dosage* viral / blood* phase ii chronic / complications chronic / drug therapy* antiviral agents / administration & dosage* treatment failure polyethylene glycols / therapeutic use hepacivirus / genetics interferons / therapeutic use sulfonamides quinoxalines / administration & dosage* eric lawitz liver cirrhosis / etiology* pmid:25467591 doi:10.1016/s0140-6736(14)61795-5 edward gane barbara haber amides benzofurans / administration & dosage* carbamates cyclopropanes imidazoles / administration & dosage*

Access

URL:
http://www.ncbi.nlm.nih.gov/pubmed/25467591

Citation

ID: 272487
Ref Key: e2015lancetefficacy
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
272487
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store